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this 6-year period have occurred in our institution. Because the 
patients that we examined had their nuclear tests performed over a 
temporally limited period at the same institution, had a high rate of 
successful follow-up and were not affected by secular trends, the study 
population meets the conventional criteria typical of an inception 
cohort (4). 
Follow-up considerations. All patients included in the study had 
undergone thallium-201 myocardial perfusion SPECT at least 1 year 
before being contacted for follow-up. Follow-up was performed by 
scripted telephone interview by people with no knowledge of the 
patient's test results. In the case of patients or patient's next of kin who 
stated that either hard events (myocardial infarction or cardiac death) 
or interventions (cardiac catheterization, coronary artery bypass sur- 
gery, percutaneous transluminal coronary angioplasty) had occurred, 
these events were confirmed by hospital records or the physician's 
office records. All hard events were confirmed by check of hospital and 
private doctor's office records by people with no knowledge of the 
patient's test results. 
Myocardial infarctions were similarly confirmed by the presence of 
appropriate cardiac enzyme and electrocardiographic changes. Our 
lost to follow-up rate of <5% in this population is testimony to our 
success in contacting patients, We agree with Ferguson that the 
determination of the exact cause of death is imprecise, but all efforts 
were made to derive the most accurate final diagnosis possible. 
Despite the numerous criticisms of Ferguson, we believe that the 
conclusions reached by our study are valid and that the study provides 
new prognostic information in an important but infrequently studied 
patient group. Ferguson raises points regarding the performance of 
multivariate survival analysis that should be asked when any such study 
is read. Although there is a need to ensure that published statistical 
analyses are performed correctly, the methodologic descriptions of 
advanced statistical analyses (as that for SPECT imaging and process- 
ing) are usually excised from the final manuscript due to the page 
limitations placed on clinical journals, A complete methods ection 
from such a manuscript may well reach the length of Ferguson's letter. 
Finally, the level of methodologic detail provided in our report is 
typical of that of other investigators in and out of our field (5-14). 
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Cardiac Syndrome X 
I read with interest the long-term study of syndrome X by Kaski et al. 
(1) and noted that 29 of their 99 patients had hypercholesterolemia. 
Unfortunately, this comprehensive study failed to provide us with a 
detailed lipid profile of the patients; no attempt was made to treat 
them; and, moreover, the lipid issue was not addressed in their 
discussion pertaining to the possible mechanisms that may cause 
ischemia in this syndrome. Abnormal coronary vasodilation has been 
observed in hypercholesterolemic subjects without evidence of athero- 
sclerosis by either coronary angiography (2) or intravascular ultra- 
sound (3). Hypercholesterolemia ay be a dominant determinant for 
abnormal endothelium-mediated vasoactivity. Indeed cholesterol- 
lowering therapy may restore and improve ndothelial function (4). 
Thus, in this subgroup of symptomatic patients it is mandatory to 
monitor and lower their lipid levels, particularly the low density 
lipoprotein fraction, and to evaluate their clinical and exercise test 
responses to such therapy. 
EDWARD G. ABINADER, MD, FRCPI 
Cardiology Institute 
Bnai Zion Medical Center 
Technion, Medical Faculty 
47 Golomb Street 
Haifa 31048, Israel 
References 
1. Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical characteristics andleft 
ventricular function. J Am Coll Cardiol 1995;25:807-14. 
2. Vita JA, Treasure CB, Nobel EG, et al. Coronary vasomotor response toaeetylcholine 
relates to risk factors for coronary artery disease. Circulation 1990;81:491-7. 
3. Reddy KG, Nair RN, Sheehan HM, Hodgson J McB. Evidence that selective endothelial 
dysfunction may occur in the absence ofangiographic or ultrasound atherosclerosis in 
patients with risk factors for atherosclerosis. J Am Coil Cardiol 1994;23:833-43. 
4. Van Boven JA, Jukema J, Zwinderman A, et al. Reduction fsilent myocardial ischemia 
by pravastatin additional to conventional treatment of patients with angina pectoris 
[abstract]. J Am Coil Cardiol 1995;25:282A. 
Reply 
I am grateful to Abinader for his comments. We are aware of the 
effects of hyperlipidemia on endothelial function. However, an assess- 
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ment of the role of plasma lipids in the pathogenesis of syndrome X
was beyond the scope of our report (1). Briefly, of the 29 patients in 
our study who had hypercholesterolemia, 17 had plasma levels that 
ranged from 5.5 to 6.5 mmol/liter and received ietary advice only. In 
the remainder, cholesterol ranged from 6.7 to 8.1 mmolhiters, and 
lipid-lowering agents were used. No correlation was observed between 
cholesterol levels (significantly reduced by treatment in 19 patients) 
and angina episodes during follow up. A comprehensive investigation 
of plasma lipids in patients with syndrome X has been recently carried 
out by Ley et al. (2) and Chauhan et al (3). Chauhan et al. (3) found 
that total plasma, high density lipoprotein (HDL) and (LDL) low 
density lipoprotein cholesterol and triglyceride levels were similar in 
patients with syndrome X and control subjects. Ley et al. (2) reported 
similar results, with the exception of lower HDL, HDL 2 and HDL 3 
cholesterol levels in patients compared with those normal control 
subjects. Thus, controversy exists as to the role of dyslipidemia in 
syndrome X. 
Our study (1) clearly showed that syndrome X is heterogeneous, 
and this finding has been further highlighted by Alpert in a recent 
editorial (4). Several pathogenetic mechanisms have been suggested. 
The presence of myocardial ischemia has been implicated by the 
occurrence of typical chest pain, ST segment depression on exercise 
testing and the transmyocardial production of lactate in some patients 
(5). In the absence of epicardial narrowing, prearteriolar microvascu- 
lar dysfunction was considered the cause of myocardial ischemia nd 
reduced coronary blood flow reserve in syndrome X. The term 
microvascular ngina was used to define this condition (6). Recently, 
both microvascular endothelial dysfunction and ischemia were docu- 
mented by Egashira et al. (7) in selected patients with syndrome X. 
However, in larger studies, abnormal coronary blood flow reserve and 
myocardial ischemia have been objectively demonstrated in only a 
minority of patients (6) or in none at all (8). Other, nonischemic 
hypotheses have been proposed: abnormal pain perception, increased 
sympathetic activity, insulin resistance and psychologic disturbances. 
In patients with syndrome X and documented ndothelial dysfunc- 
tion (probably aminority), dyslipidemia may play a role and should be 
carefully investigated. However, it is premature toassume that control 
of hyperlipidemia will necessarily essen symptoms inthese patients. In 
assessing the role of dyslipidemia, the complex interactions between 
lipid levels and other alterations commonly observed in syndrome X, 
such as estrogen deficiency, insulin resistance and endothelial function, 
should be considered because it may be inappropriate ostudy any of 
these in isolation. Also relevant o Abinader's comments i the fact 
that coronary arteriography is used to classify patients with syndrome 
X. Coronary arteriography, particularly computer-assisted quantita- 
tion, is a reliable method to identify lumen narrowing. However, 
angiography is less capable of identifying early atherosclerotic lesions 
that have not yet produced lumen diameter eductions. Thus, in 
syndrome X, undetected atheroma-related ndothelial dysfunction 
may occur that could be responsible for "microvascular ngina." This 
dysfunction may or may not be affected by lipid lowering agents. 
Too often physicians have erroneously attempted to identify and 
treat a single etiologic mechanism in syndrome X, and management 
has been empiric in the majority of cases. Although Abinader's 
suggestion is interesting, carefully designed studies of the correlation 
of endothelial function and symptoms, as well as the effects of 
lipid-lowering interventions on long-term clinical improvement, are 
mandatory before costly and time-consuming investigations are rec- 
ommended for clinical management of syndrome X. 
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